Metacrine
2014
FOUNDED
PRIVATE
STATUS
21-30
EMPLOYEES
Series B
LATEST DEAL TYPE
$22M
LATEST DEAL AMOUNT
7
INVESTORS
Description
Provider of biotechnology services intended to develop innovative drug therapeutics for metabolic diseases. The company's biotechnology services specializes in dealing with class of insulin sensitizer having the potential to correct underlying defects in type 2 diabetes with fewer safety issues than existing agents and a compound that works in the intestine, enabling patients to avail two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Primary Office
- 12780 El Camino Real
- Suite 301
- San Diego, CA 92130
- United States
+1 (858) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Metacrine’s full profile, request a free trial.
Metacrine Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series B) | 07-Dec-2017 | $22M | 000.00 | 0000 | Completed | Startup |
| 1. Early Stage VC (Series A) | 02-Nov-2016 | 000.00 | 000.00 | 000.00 | Completed | Startup |
Metacrine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 000 |
| Series A | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 00.000 |
Metacrine Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| New Enterprise Associates | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| The Longevity Fund | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| ARCH Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| EcoR1 Capital | Hedge Fund | Minority | 000 0000 | 000000 0 |
Metacrine Executive Team (9)
2 Former Executives
You’re viewing 5 of 9 executives. Get the full list »Metacrine Board Members (6)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Amir Nashat Ph.D | Polaris Partners | Board Member | 000 0000 | |
| Carol Gallagher | New Enterprise Associates | Board Member | 000 0000 | |
| Kristina Burow | ARCH Venture Partners | Board Member | 000 0000 | |
| Richard Heyman Ph.D | Self | Executive Chairman & Co-Founder | 000 0000 | |
| Robert Adelman MD | venBio | Board Member | 000 0000 |